Learn more and complete the online clinic submission form here.ĬVS Health has administered more than 17 million COVID-19 vaccines in long-term care and retail settings and will be offering vaccinations at more than 9,600 CVS Pharmacy locations across 50 states, Puerto Rico, and Washington, D.C. Schools, businesses and other organizations with more than 48 participants can sponsor an on-site clinic with COVID-19 vaccines administered by CVS Heath for eligible populations. Return Ready, CVS Health's comprehensive COVID-19 testing and vaccine solution for businesses, schools and other organizations will also meet the expanded eligibility for adolescents ages 12 to 15. The scheduling tool will only display appointments at CVS Pharmacy locations that have the Pfizer-BioNTech vaccine once the patient's age is provided. "Offering vaccinations to younger populations at thousands of locations across the country brings us one step closer to prevailing over the pandemic."īecause the Pfizer-BioNTech vaccine is the only FDA-authorized COVID-19 vaccine for adolescents in this age group, patients are encouraged to schedule an appointment online at cvs.com or through the CVS Pharmacy app to ensure availability. "With every new wave of eligibility our teams have worked around the clock to ensure vaccine access as soon as possible," said Karen Lynch, President and Chief Executive Officer, CVS Health. Parental or legal guardian consent is required, and children must be accompanied by an adult. Starting tomorrow, May 13, participating CVS Pharmacy locations will begin administering the Pfizer-BioNTech vaccine to this newly eligible population. CVS Health (NYSE: CVS) announced that COVID-19 vaccine appointments for adolescents ages 12 to 15 are now available for scheduling at more than 5,600 CVS Pharmacy locations nationwide, following Food and Drug Administration (FDA) Emergency Use Authorization of the Pfizer-BioNTech vaccine for this age group. The company now expects fiscal 2023 adjusted earnings per share of $4.00 to $4.05, from $4.45 to $4.65 previously.WOONSOCKET, R.I. Same-store sales at its pharmacies, however, rose 9.8% and beat estimates of 8.8%, mainly due to higher drug prices. In the third quarter, Walgreens reported a 0.2% fall in same-store sales at its retail division, compared with estimates of a 2.1% rise, mainly due to lower COVID testing and sluggish demand for cough and cold medicines. The company said it had increased the target of an ongoing cost-cutting program to counter those pressures. I still think they're learning how to target their promotions better and maximize their loyalty card," said Jonas.Īlso weighing on shares, the pharmacy chain said its new healthcare business, through which it operates doctors' offices, missed Walgreens' target for sales growth due to a weak respiratory disease season. "I think there's some execution issues there, too. REUTERS/Andrew Kelly/File Photoīrewer said higher inflation rates, lower tax refunds and other macroeconomic issues were causing consumers to pull back on discretionary spending. Signage is seen outside of a Walgreens, owned by the Walgreens Boots Alliance, Inc., in Manhattan, New York City, U.S., November 26, 2021. It has around 13,000 locations across the United States, Europe and Latin America. Walgreens said on its conference call it now plans to close 300 additional locations in the United Kingdom and 150 in the United States. probably has some impact on CVS and Rite Aid," Gabelli Funds portfolio manager Jeff Jonas said. "Very few people are getting either rapid tests or the actual PCR nasal swab tests. , with the stocks closing down 11%% and 1.6% respectively. The forecast cut also hit shares of Rite Aid (RAD.N) and larger rival CVS Health (CVS.N) Walgreens' shares closed at $28.64, hitting their lowest in more than 11 years, after the company slashed its profit forecast for the year. "Similar to other retailers, we've been impacted by the rapid softening of the macro environment and a more cautious and value-driven consumer," Walgreens CEO Rosalind Brewer told investors. The end of the COVID emergency in May led to a steep drop in COVID vaccines and testing, Walgreens executives said, while penny-pinching customers hunted for discounted items, shunning normal-priced consumer health products. June 27 (Reuters) - Walgreens Boots Alliance (WBA.O) on Tuesday warned that lower spending by inflation-weary consumers and a hit from a larger-than-expected drop in COVID-19 product sales would likely persist into next year, sending its shares down by 9%.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |